Search

Search Constraints

You searched for: Author/Creator Debled, Marc

Search Results

1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019)

3. Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. (September 2019)

4. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. (June 2018)

5. Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Issue 12 (20th June 2019)

6. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. (August 2020)

7. Contemporary outcomes of metastatic breast cancer among 22, 000 women from the multicentre ESME cohort 2008–2016. (April 2020)

9. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort. (June 2022)

10. Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study. (March 2022)